Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females

Most studies on ketosis have focused on short-term effects, male athletes, or weight loss. Hereby, we studied the effects of short-term ketosis suppression in healthy women on long-standing ketosis. Ten lean (BMI 20.5 ± 1.4), metabolically healthy, pre-menopausal women (age 32.3 ± 8.9) maintaining nutritional ketosis (NK) for > 1 year (3.9 years ± 2.3) underwent three 21-day phases: nutritional ketosis (NK; P1), suppressed ketosis (SuK; P2), and returned to NK (P3). Adherence to each phase was confirmed with daily capillary D-beta-hydroxybutyrate (BHB) tests (P1 = 1.9 ± 0.7; P2 = 0.1 ± 0.1; and P3 = 1.9 ± 0.6 mmol/L). Ageing biomarkers and anthropometrics were evaluated at the end of each phase. Ketosis suppression significantly increased: insulin, 1.78-fold from 33.60 (± 8.63) to 59.80 (± 14.69) mmol/L (p = 0.0002); IGF1, 1.83-fold from 149.30 (± 32.96) to 273.40 (± 85.66) µg/L (p = 0.0045); glucose, 1.17-fold from 78.6 (± 9.5) to 92.2 (± 10.6) mg/dL (p = 0.0088); respiratory quotient (RQ), 1.09-fold 0.66 (± 0.05) to 0.72 (± 0.06; p = 0.0427); and PAI-1, 13.34 (± 6.85) to 16.69 (± 6.26) ng/mL (p = 0.0428). VEGF, EGF, and monocyte chemotactic protein also significantly increased, indicating a pro-inflammatory shift. Sustained ketosis showed no adverse health effects, and may mitigate hyperinsulinemia without impairing metabolic flexibility in metabolically healthy women.

[1]  B. Elliott,et al.  Bio-Hacking Better Health—Leveraging Metabolic Biochemistry to Maximise Healthspan , 2023, Antioxidants.

[2]  R. Halwani,et al.  Assessing the Link between Diabetic Metabolic Dysregulation and Breast Cancer Progression , 2023, International journal of molecular sciences.

[3]  A. Bianco,et al.  The Effects of Ketogenic Diet on Insulin Sensitivity and Weight Loss, Which Came First: The Chicken or the Egg? , 2023, Nutrients.

[4]  S. O'toole,et al.  MCP‐1 expression in breast cancer and its association with distant relapse , 2023, Cancer medicine.

[5]  Kyong Park,et al.  Carbohydrate-based diet may increase the risk of cardiovascular disease: A pooled analysis of two prospective cohort studies. , 2023, Clinical nutrition.

[6]  M. S. Ryu,et al.  Contribution of monocyte and macrophage extracellular traps to neutrophilic airway inflammation in severe asthma. , 2023, Allergology international : official journal of the Japanese Society of Allergology.

[7]  Gang Liu,et al.  Aging, Plasminogen Activator Inhibitor 1, Brain Cell Senescence, and Alzheimer’s Disease , 2023, Aging and disease.

[8]  A. O’Halloran,et al.  Sustaining an ageing population: The role of micronutrients in frailty and cognitive impairment. , 2023, The Proceedings of the Nutrition Society.

[9]  Jiwon Kwak,et al.  Serum γ-glutamyltransferase level and incidence risk of metabolic syndrome in community dwelling adults: longitudinal findings over 12 years , 2023, Diabetology & Metabolic Syndrome.

[10]  C. Ingallina,et al.  New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food , 2023, Nutrients.

[11]  Arwa R. Althaher An Overview of Hormone-Sensitive Lipase (HSL) , 2022, TheScientificWorldJournal.

[12]  V. Steenkamp,et al.  The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy , 2022, International journal of molecular sciences.

[13]  R. Rizzo,et al.  The Evolution of Ketosis: Potential Impact on Clinical Conditions , 2022, Nutrients.

[14]  Zhenfu Wang,et al.  Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases , 2022, Aging and disease.

[15]  R. Jha,et al.  A Ketogenic Diet is Effective in Improving Insulin Sensitivity in Individuals with Type 2 Diabetes. , 2022, Current diabetes reviews.

[16]  Yihai Cao,et al.  The impact of VEGF on cancer metastasis and systemic disease. , 2022, Seminars in cancer biology.

[17]  C. Ebbeling,et al.  Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial , 2022, Diabetes care.

[18]  E. Giovannucci,et al.  Association between IGF‐1 levels ranges and all‐cause mortality: A meta‐analysis , 2022, Aging cell.

[19]  H. Qin,et al.  Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations , 2022, Signal Transduction and Targeted Therapy.

[20]  Linghua Mei,et al.  Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases , 2022, Medicine.

[21]  Ling Liu,et al.  Fasting Induces a Highly Resilient Deep Quiescent State in Muscle Stem Cells via Ketone Body Signaling , 2022, bioRxiv.

[22]  Jinxin Lan,et al.  MCP-1 targeting: Shutting off an engine for tumor development , 2021, Oncology letters.

[23]  Z. Shakoor,et al.  Expression of VEGF, EGF and HGF in early- and late-stage colorectal cancer. , 2021, Molecular and clinical oncology.

[24]  Peijie Chen,et al.  β-hydroxybutyrate as an Anti-Aging Metabolite , 2021, Nutrients.

[25]  I. Kraev,et al.  Preliminary Investigations Into the Effect of Exercise-Induced Muscle Damage on Systemic Extracellular Vesicle Release in Trained Younger and Older Men , 2021, Frontiers in Physiology.

[26]  K. Brookler,et al.  Rethinking Fragility Fractures in Type 2 Diabetes: The Link between Hyperinsulinaemia and Osteofragilitas , 2021, Biomedicines.

[27]  C. V. van Karnebeek,et al.  The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease. , 2021, The international journal of biochemistry & cell biology.

[28]  V. Viswanathan,et al.  Hyperglucagonemia and impaired insulin sensitivity are associated with development of prediabetes and type 2 diabetes - A study from South India. , 2021, Diabetes & metabolic syndrome.

[29]  B. Elliott,et al.  Metabolic Phenotypes and Step by Step Evolution of Type 2 Diabetes: A New Paradigm , 2021, Biomedicines.

[30]  I. Shelef,et al.  Effect of Dietary Strategies on Respiratory Quotient and Its Association with Clinical Parameters and Organ Fat Loss: A Randomized Controlled Trial , 2021, Nutrients.

[31]  V. Ravichandiran,et al.  MCP-1: Function, regulation, and involvement in disease , 2021, International Immunopharmacology.

[32]  R. Ajjan,et al.  PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target , 2021, International journal of molecular sciences.

[33]  P. Declerck,et al.  A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? , 2021, International journal of molecular sciences.

[34]  M. Nakao,et al.  Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation , 2021, Nature Metabolism.

[35]  A. Holland-Winkler,et al.  Reliability and diagnostic performance of a new blood ketone and glucose meter in humans , 2021, Journal of the International Society of Sports Nutrition.

[36]  T. Hoppe,et al.  Build-UPS and break-downs: metabolism impacts on proteostasis and aging , 2021, Cell death and differentiation.

[37]  D. Yee,et al.  Disrupting Insulin and IGF Receptor Function in Cancer , 2021, International journal of molecular sciences.

[38]  Xiaojie Yuan,et al.  Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis , 2020, Nutrition & Diabetes.

[39]  F. Flamigni,et al.  Nutrients and Pathways that Regulate Health Span and Life Span , 2020, Geriatrics.

[40]  Wei Xu,et al.  Relationship Between Serum Gamma-Glutamyl Transferase Level and Impaired Fasting Glucose Among Chinese Community-Dwelling Adults: A Follow-Up Observation of 6 Years. , 2020, Metabolic syndrome and related disorders.

[41]  R. Kavalar,et al.  The value of uPA and PAI-1 levels in triple negative breast cancer , 2020 .

[42]  S. Auvin,et al.  Ketogenic diet and Neuroinflammation , 2020, Epilepsy Research.

[43]  J. DiNicolantonio,et al.  Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management , 2020, Open Heart.

[44]  R. Holtzer,et al.  Insulin-like Growth Factor-1 and IGF Binding Proteins Predict All-Cause Mortality and Morbidity in Older Adults , 2020, Cells.

[45]  A. Foroumadi,et al.  A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. , 2020, Bioorganic chemistry.

[46]  B. Zhang,et al.  Update on the synergistic effect of HSL and insulin in the treatment of metabolic disorders , 2019, Therapeutic advances in endocrinology and metabolism.

[47]  B. Kofler,et al.  Ketogenic diet in the treatment of cancer – Where do we stand? , 2019, Molecular metabolism.

[48]  G. Paradies,et al.  Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease: Molecular and Pharmacological Aspects , 2019, Cells.

[49]  S. Uemoto,et al.  Up-regulation of FOXO1 and reduced inflammation by β-hydroxybutyric acid are essential diet restriction benefits against liver injury , 2019, Proceedings of the National Academy of Sciences.

[50]  J. Masumoto,et al.  The role of interleukin-1 in general pathology , 2019, Inflammation and Regeneration.

[51]  L. Piemonti,et al.  Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes , 2019, Nutrients.

[52]  J. Stevens,et al.  Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. , 2019, Metabolic syndrome and related disorders.

[53]  A. Damjanović,et al.  Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy , 2019, BMC Cancer.

[54]  J. Holst,et al.  Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. , 2018, Metabolic syndrome and related disorders.

[55]  M. Rubin,et al.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors , 2018, Nature.

[56]  A. Bronisz,et al.  Pregnancy Ketonemia and Development of the Fetal Central Nervous System , 2018, International journal of endocrinology.

[57]  F. Villamena,et al.  Nutritional Ketosis and Mitohormesis: Potential Implications for Mitochondrial Function and Human Health , 2018, Journal of nutrition and metabolism.

[58]  P. Reynier,et al.  How Can a Ketogenic Diet Improve Motor Function? , 2018, Front. Mol. Neurosci..

[59]  M. Bache,et al.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume , 2018, Strahlentherapie und Onkologie.

[60]  Saran Kumar,et al.  Hyperglycemia Impairs Neutrophil Mobilization Leading to Enhanced Metastatic Seeding. , 2017, Cell Reports.

[61]  B. Johansson,et al.  Gamma-Glutamyltransferase (GGT) as a biomarker of cognitive decline at the end of life: contrasting age and time to death trajectories , 2017, International Psychogeriatrics.

[62]  J. DiNicolantonio,et al.  Postprandial insulin assay as the earliest biomarker for diagnosing pre-diabetes, type 2 diabetes and increased cardiovascular risk , 2017, Open Heart.

[63]  A. Itai,et al.  Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination , 2017, Oncotarget.

[64]  J. B. Jensen,et al.  Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients , 2017, Oncotarget.

[65]  S. Griffey,et al.  A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. , 2017, Cell metabolism.

[66]  E. Verdin,et al.  β-Hydroxybutyrate: A Signaling Metabolite. , 2017, Annual review of nutrition.

[67]  T. Kohlmann,et al.  Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network , 2017, Gynecologic and Obstetric Investigation.

[68]  Q. Feng,et al.  High glucose levels promote the proliferation of breast cancer cells through GTPases , 2017, Breast cancer.

[69]  K. Clarke,et al.  Ketone bodies mimic the life span extending properties of caloric restriction , 2017, IUBMB life.

[70]  Marcelo González,et al.  Pro-angiogenic Role of Insulin: From Physiology to Pathology , 2017, Front. Physiol..

[71]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[72]  R. Ortiz,et al.  Thyroid Hormone Regulation and Insulin Resistance: Insights From Animals Naturally Adapted to Fasting. , 2017, Physiology.

[73]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[74]  J. Tan-Shalaby,et al.  Ketogenic Diets and Cancer: Emerging Evidence. , 2017, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[75]  K. Reiss,et al.  Regulation of Ketone Body Metabolism and the Role of PPARα , 2016, International journal of molecular sciences.

[76]  Xuemei Wu,et al.  Oxidative damage induces MCP-1 secretion and macrophage aggregation in age-related macular degeneration (AMD) , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

[77]  M. Duffy,et al.  Validated biomarkers: The key to precision treatment in patients with breast cancer. , 2016, Breast.

[78]  G. Pacini,et al.  Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus , 2016, Endocrine reviews.

[79]  M. Díaz-Flores,et al.  High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells , 2016, Cellular Oncology.

[80]  J. Gibbins,et al.  Platelet signaling: a complex interplay between inhibitory and activatory networks , 2016, Journal of thrombosis and haemostasis : JTH.

[81]  Y. Abed,et al.  Obesity and inflammation: the linking mechanism and the complications , 2016, Archives of medical science : AMS.

[82]  W. Kraemer,et al.  Metabolic characteristics of keto-adapted ultra-endurance runners. , 2016, Metabolism: clinical and experimental.

[83]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[84]  B. Duncan,et al.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies , 2016, Scientific Reports.

[85]  C. Crofts Hyperinsulinemia: A unifying theory of chronic disease? , 2015 .

[86]  P. Urbánek,et al.  Redox regulation of FoxO transcription factors , 2015, Redox biology.

[87]  Voichita D. Marinescu,et al.  Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells , 2015, Oncotarget.

[88]  R. Chen,et al.  High glucose promotes gastric cancer chemoresistance in vivo and in vitro , 2015, Molecular medicine reports.

[89]  T. Seyfried,et al.  The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer , 2015, Nutrition & Metabolism.

[90]  M. Laville,et al.  Insulin Resistance is Associated with MCP1-Mediated Macrophage Accumulation in Skeletal Muscle in Mice and Humans , 2014, PloS one.

[91]  A. Brunet,et al.  FOXO transcription factors: key regulators of cellular quality control. , 2014, Trends in biochemical sciences.

[92]  E. Verdin,et al.  Ketone bodies as signaling metabolites , 2014, Trends in Endocrinology & Metabolism.

[93]  Mukesh G. Gohel,et al.  Serum GGT activity and hsCRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control , 2013, Journal of Diabetes & Metabolic Disorders.

[94]  Á. Valverde,et al.  Insulin directly stimulates VEGF-A production in the glomerular podocyte. , 2013, American journal of physiology. Renal physiology.

[95]  Eric Verdin,et al.  Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.

[96]  T. Kadowaki,et al.  Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice , 2012, Diabetologia.

[97]  Han Liu,et al.  High Glucose Promotes Pancreatic Cancer Cell Proliferation via the Induction of EGF Expression and Transactivation of EGFR , 2011, PloS one.

[98]  G. López-Castejón,et al.  Understanding the mechanism of IL-1β secretion , 2011, Cytokine & growth factor reviews.

[99]  B. Balkau,et al.  Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women , 2011, Diabetes.

[100]  L. Bostad,et al.  Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy , 2010, BMC urology.

[101]  K. Schmid,et al.  Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer , 2010, Cancer.

[102]  K. Kinzig,et al.  Insulin sensitivity and glucose tolerance are altered by maintenance on a ketogenic diet. , 2010, Endocrinology.

[103]  B. Draznin,et al.  Mitogenic action of insulin: friend, foe or ‘frenemy’? , 2010, Diabetologia.

[104]  J. Zavadil,et al.  Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1. , 2009, Molecular endocrinology.

[105]  H. Tissenbaum,et al.  Converging Pathways in Lifespan Regulation , 2009, Current Biology.

[106]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[107]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[108]  R. Balsara,et al.  Plasminogen activator inhibitor-1: The double-edged sword in apoptosis , 2008, Thrombosis and Haemostasis.

[109]  Katsuhiko Yano,et al.  FOXO3A genotype is strongly associated with human longevity , 2008, Proceedings of the National Academy of Sciences.

[110]  Z. Tulassay,et al.  Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer , 2008, BMC Cancer.

[111]  A. Hamsten,et al.  Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. , 2008, American journal of physiology. Endocrinology and metabolism.

[112]  M. Juárez-Oropeza,et al.  The Respiratory Exchange Ratio is Associated with Fitness Indicators Both in Trained and Untrained Men: A Possible Application for People with Reduced Exercise Tolerance , 2008, Clinical medicine. Circulatory, respiratory and pulmonary medicine.

[113]  A. Puisieux,et al.  Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer , 2006, BMC Cancer.

[114]  D. Loskutoff,et al.  Molecular mechanisms of tumor necrosis factor‐α‐mediated plasminogen activator inhibitor‐1 expression in adipocytes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[115]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[116]  M. Kiechle,et al.  Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer , 2004, Thrombosis and Haemostasis.

[117]  Claudio Franceschi,et al.  Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. , 2003, American journal of physiology. Endocrinology and metabolism.

[118]  P. Morange,et al.  Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk , 2003, Journal of thrombosis and haemostasis : JTH.

[119]  D. Loskutoff,et al.  Monocyte chemoattractant protein 1 in obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Martin Holzenberger,et al.  IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice , 2003, Nature.

[121]  D. Haro,et al.  Down-regulation of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by insulin: the role of the forkhead transcription factor FKHRL1. , 2002, The Biochemical journal.

[122]  D. Dunger,et al.  Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. , 2002, Journal of the National Cancer Institute.

[123]  L. Devy,et al.  The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  D. Loskutoff,et al.  Insulin Continues to Induce Plasminogen Activator Inhibitor 1 Gene Expression in Insulin-Resistant Mice and Adipocytes , 2000, Molecular medicine.

[125]  E. Van Obberghen,et al.  Insulin and Insulin-like Growth Factor-I Induce Vascular Endothelial Growth Factor mRNA Expression via Different Signaling Pathways* , 2000, The Journal of Biological Chemistry.

[126]  D. Accili,et al.  Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. , 2000, Endocrinology.

[127]  G. Brooks,et al.  Respiratory gas-exchange ratios during graded exercise in fed and fasted trained and untrained men. , 1999, Journal of applied physiology.

[128]  G. Siest,et al.  gamma-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. , 1998, Free radical biology & medicine.

[129]  D. Accili,et al.  Effect of Insulin on Farnesyltransferase , 1998, The Journal of Biological Chemistry.

[130]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[131]  C. Martínez-A,et al.  The Coordinated Action of CC Chemokines in the Lung Orchestrates Allergic Inflammation and Airway Hyperresponsiveness , 1998, The Journal of experimental medicine.

[132]  M. Goalstone,et al.  What does insulin do to Ras? , 1998, Cellular signalling.

[133]  M. Goalstone,et al.  Hyperinsulinemia potentiates activation of p21Ras by growth factors. , 1997, Endocrinology.

[134]  P. Morange,et al.  Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.

[135]  C. Delgado,et al.  Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[136]  B. Bennett,et al.  Plasminogen activator inhibitor (PAI‐1) in plasma and platelets , 1988, British journal of haematology.

[137]  D. Hill,et al.  Insulin as a Growth Factor , 1985, Pediatric Research.

[138]  E. Ravussin,et al.  Respiratory quotients lower than 0.70 in ketogenic diets. , 1980, The American journal of clinical nutrition.

[139]  L. Hayflick,et al.  The serial cultivation of human diploid cell strains. , 1961, Experimental cell research.

[140]  N. El-Badri,et al.  Pericytes: The Role of Multipotent Stem Cells in Vascular Maintenance and Regenerative Medicine. , 2018, Advances in experimental medicine and biology.

[141]  Victoria S. Sprung,et al.  A pilot study to explore the role of a low-carbohydrate intervention to improve GGT levels and HbA 1 c , 2015 .

[142]  S Kumanyika,et al.  Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist–Hip Ratio , 2010, European Journal of Clinical Nutrition.

[143]  Y. Iwadate,et al.  High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. , 2008, Anticancer research.

[144]  S. Grundy Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[145]  J. Seidell,et al.  The public health impact of obesity. , 2001, Annual review of public health.